Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer

被引：0

作者：

Mattos, Bruna RaphaeliSilva ^{[1
]}

Cesca, Marcelle Goldner ^{[1
]}

Leite, Luciana de Moura ^{[1
]}

Tavares, Monique Celeste ^{[1
]}

Silva, Sinara Figueiredo ^{[1
]}

Pirolli, Rafaela ^{[1
]}

Fogassa, Camilla AlbinaZanco ^{[1
]}

Silva, Erick Figueiredo ^{[1
]}

Rocha, Francisca Giselle ^{[1
]}

Loose, Simone Klug ^{[1
]}

Campos, Fernando AugustoBatista ^{[1
]}

Sanches, Solange Moraes ^{[1
]}

de Lima, Vladmir ClaudioCordeiro ^{[1
]}

Ponde, Noam Falbel ^{[1
]}

机构：

[1] AC Camargo Canc Ctr, Sao Paulo, Brazil

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS4-40

引用

页数：2

共 50 条

[31] Impact of neoadjuvant HER2-directed therapy on HER2 status in breast cancer
Manguso, Nicholas
Johnson, Jeffrey
Basho, Reva Kakkar
McArthur, Heather L.
Tanaka, Hisashi
Giuliano, Armando E.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[32] Alterations in HER2 status and outcome following neoadjuvant chemotherapy in HER2-positive breast cancer (BC)
Ng, Dianna
Krings, Gregor
Yau, Christina
White, Kristie
Hou, Jie
Chua, Anthony
Grenert, James P.
Chen, Yunn-Yi
CANCER RESEARCH, 2015, 75
[33] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
Zhao, Jing
Zhang, Chao
Suo, Aili
Shi, Qiuying
Wei, Zhimin
Li, Zaibo
Krishnamurti, Uma
Li, Xiaoxian
LABORATORY INVESTIGATION, 2019, 99
[34] Evaluation of analytical accuracy of HER2 status in patients with breast cancer Comparison of HER2 GPA with HER2 IHC and HER2 FISH
Jensen, Steffen Grann
Thomas, Peter Engel
Christensen, Ib Jarle
Balslev, Eva
Hansen, Alastair
Hogdall, Estrid
APMIS, 2020, 128 (11) : 573 - 582
[35] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
Bhargava, R.
MODERN PATHOLOGY, 2012, 25 : 26A - 26A
[36] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, Ron
Kavuri, Shyam M.
Searleman, Adam C.
Shen, Wei
Shen, Dong
Koboldt, Daniel C.
Monsey, John
Goel, Nicholas
Aronson, Adam B.
Li, Shunqiang
Ma, Cynthia X.
Ding, Li
Mardis, Elaine R.
Ellis, Matthew J.
CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
[37] Evaluating Low HER2 Status in Breast Cancer Cases with Absent and Low HER2 Protein Expression
Ardor, Gokce
Komforti, Miglena
Hanna, Helena
Nassar, Aziza
LABORATORY INVESTIGATION, 2023, 103 (03) : S94 - S95
[38] HEr2 testing in neoadjuvant breast cancer trials - improved concordance of HER2 status in different pathology laboratories
Pfitzner, B.
Lederer, B.
Lindner, J.
Solbach, C.
Engels, K.
Rezai, M.
Dohnal, K.
Tesch, H.
Hansmann, M. -L.
Salat, C.
Beer, M.
Schneeweiss, A.
Sinn, P.
von Minckwitz, G.
Denkert, C.
Loibl, S.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 56 - 56
[39] Neoadjuvant therapy in patients with triple negative and HER2 positive early breast cancer
Harbeck, N.
BREAST, 2017, 32 : S18 - S18
[40] Loss of HER2 after neoadjuvant treatment of HER2+early breast cancer
Morales, S.
Gasol Cudos, A.
Rodriguez Galindo, A.
Velasco, A.
Canosa Morales, C.
Sanchez Guzman, D. -R.
Mele Olive, J.
ANNALS OF ONCOLOGY, 2020, 31 : S51 - S51

← 1 2 3 4 5 →